CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.

@article{Muramatsu2011CD20negativeEV,
  title={CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.},
  author={Hideki Muramatsu and Yoshiyuki Takahashi and Yoshie Shimoyama and Sayoko Doisaki and Nobuhiro Nishio and Yoshinori Ito and Asahito Hama and Akira Shimada and Hiroshi Yagasaki and Masafumi Ito and Seiji Kojima},
  journal={International journal of hematology},
  year={2011},
  volume={93 6},
  pages={779-781}
}
Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT). Monitoring of EBV DNA in high-risk patients with subsequent pre-emptive rituximab treatment is highly effective, and can prevent EBV-associated disease following HSCT… CONTINUE READING